Search

Displaying results 1301 - 1310 of 1803 in total
  1. Drug

    Rezafungin

    go.drugbank.com/drugs/DB16310
    ApprovedInvestigational

    Rezafungin has a half-life higher than 130 hours and can be administered once a week instead of daily.

  2. Drug

    Chromic chloride

    go.drugbank.com/drugs/DB09129
    Approved

    Chromic chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).

    Mixtures: One-A-day Advance Men's, One Tablet Daily Mens Formula
  3. Drug

    Virginiamycin M1

    go.drugbank.com/drugs/DB01669
    Experimental

    Pristinamycin IIA is a macrolide antibiotic, a member of the streptogramin A group of antibiotics, and one component of pristinamycin. It is produced by Streptomyces graminofaciens and other bacteria.

  4. Drug

    Eteplirsen

    go.drugbank.com/drugs/DB06014
    ApprovedInvestigational

    Eteplirsen is a synthetic antisense oligonucleotide and a phosphorodiamidate morpholino oligomer. It consists of a six-membered morpholino ring replacing the five-membered ribofuranosyl rings found in natural DNA and RNA. Duchenne muscul...

  5. Drug

    Milrinone

    go.drugbank.com/drugs/DB00235
    ApprovedInvestigational

    myocardial ischemia, cardiomyopathy, or other cardiac insults, heart failure results from an inability of the heart to perfuse peripheral tissues with sufficient oxygen and metabolites, resulting in complex

  6. Drug

    Cefixime

    go.drugbank.com/drugs/DB00671
    ApprovedInvestigational

    [T894, T322] Additionally, third-generation cephalosporins have been shown to have more stability in the presence of beta-lactamases compared to first- and second-generation cephalosporins.

  7. Drug

    Momelotinib

    go.drugbank.com/drugs/DB11763
    ApprovedInvestigational

    Momelotinib is a Janus Kinase 1 (JAK1) and 2 (JAK2) inhibitor. It is a competitive inhibitor of JAK ATP binding. First approved by the FDA on September 15, 2023, momelotinib is used to treat myelofibrosis. Myelofibrosis (MF) is a group o...

  8. Drug

    Letermovir

    go.drugbank.com/drugs/DB12070
    ApprovedInvestigational

    [L1021] It is the first of a new class of CMV anti-infectives called DNA terminase complex inhibitors.[A31290] Letermovir has recieved both priority and orphan drug status from the FDA.

    Categories: DNA Terminase Complex Inhibitors, Cytomegalovirus DNA Terminase Complex Inhibitor
  9. Drug

    Idarucizumab

    go.drugbank.com/drugs/DB09264
    Approved

    As a direct acting oral anticoagulant (DOAC), one of the risks associated with the use of dabigatran includes bleeding, espeically when given to patients at increased risk (elderly, chronic kidney disease

  10. Drug

    Anthrax vaccine

    go.drugbank.com/drugs/DB11003
    ApprovedInvestigational

    [L47526] It is considered one of the most likely agents to be used in a biological attack.

    Categories: Complex Mixtures